Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy.

Explores the dual GIP/GLP-1 receptor agonist's impact on kidney and cardiovascular outcomes in patients with chronic kidney disease.